Ok, so assuming that the FDA doesn't grant an EUA for the M2M population but requires Cytodyn to conduct a Phase 3 trial. What would that look like? Just change the N trial size by what, maybe 20 or 30 patients? Change the "primary" end point to NEWS2? In my mind, it's just a repeat of the Phase 2 trial with highly similar results, no?? It'll just be time wasted and with it, more lives affected.